Gastrointestinal Drugs Market of Asia-Pacific Predict by 2022: Abbott, Allergan Plc, AstraZeneca, Eli Lilly Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Pfizer Inc.

The Asia market is expected to grow rapidly in the coming years. After studying and analyzing the market, it shows that this region has good growth potential due to rising unhealthy eating habits and unhygienic conditions. Diarrhea, acidity and gastric cancer are the major diseases in this region. The Asia Gastrointestinal Drugs Market is expected to grow at a CAGR of 6.1% during the forecast period 2017-2023.

The incident of ulcerative colitis and Crohn's disease is increasing continuously in Asia. The highest incidence was mainly reported in Korea, China, Hong Kong, and India. Ulcerative colitis is one of the most common GI diseases in Asian countries. South Korea and Singapore have experienced a sharp increase in the rate of ulcerative colitis over the past decade. As per research, increasing smoking rate, growing urbanization, poor diet, and hereditary are the major causes of GI diseases.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/633 .

Smoking rates remain persistently high throughout Asian countries, especially, developing countries such as China and India. According to the World Health Organization (WHO), in 2010, over 300 million smokers were present in China accounting for nearly one-third of the world's total. These factors are responsible for the growth of the market.

Taste the market data and market information presented through more than 86 market data tables and figures spread over 106 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “gastrointestinal drugs market research report–Asia forecast till 2023.”

Companies Involved:

Some of the key players in this market are Abbott, Allergan Plc., AstraZeneca, Eli Lilly Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Pfizer Inc., Valeant Pharmaceuticals, and others.

Research Methodology:

Source: World Health Organization, Centers for Disease Control and Prevention, expert interview market research future analysis, annual report, white paper, company presentation

Browse More Report @ https://www.marketresearchfuture.com/reports/asia-pacific-gastrointestinal-drugs-market-633 .

Market Segmentation:

The Asia gastrointestinal drugs market is segmented on the basis of region: China, India, Republic of Korea, and Rest of Asia.

Developing nations, for instance, India is experiencing high demand for gastrointestinal disorder drugs. Major pharmaceuticals drug manufacturers are using their technology and services to develop new drugs for gastrointestinal diseases to meet growing demand.

Malaysian pharmaceutical market is growing rapidly due to increasing wealthy and middle class population, geriatric population, urbanization, and high quality healthcare & medicines. Healthcare in Malaysia is segmented into a government universal healthcare scheme and a private healthcare system. The healthcare private system is growing rapidly, especially, in urban areas.

Thailand is witnessing a significant growth in the healthcare market and is expected to grow over the forecast period due to rapid growth in the pharmaceutical industry. According to the Thailand Board of Investment, Thai pharmaceutical is largest market across this region. The government of Thailand has implemented many long-term strategic plans and policies to support the pharmaceutical industry. Around 160 Thai companies that import pharmaceutical ingredients produce and sell generic drugs to Thai consumers. The export of pharmaceutical products in Thailand has grown steadily over the past five years and most of the products export to nearby countries, for instance, Myanmar, Vietnam, and Cambodia.

The prevalence of GI diseases is high in Asia, where tuberculosis is a common disease and it shows similar symptoms alike GI diseases. According to the WHO in 2015, the largest number of new TB cases were reported in Asia and India, Indonesia, China, and Pakistan accounted for over 40% of the new TB cases. To handle the rising prevalence of GI diseases, manufacturers have increased the investment in the research and development of innovative and effective drugs. Government of Asian countries are also supporting the manufacturers for their research to balance the demand and supply of the product.

Key Findings:

The Asia gastrointestinal drugs market is expected to reach USD 20,772.4 million by 2023 at a CAGR of 6.1%

Acid neutralizers segment accounted for the largest market share with 33.3% of the Asia gastrointestinal drug market, by drug types in 2016

In 2016, Esophagus diseases segment accounted for the major share of the market as it was the most widely occurring GI disease. The Asia esophagus diseases market by type of diseases is expected to reach USD 7,427.6 million by 2023, growing at a CAGR of 6.32% from 2017 to 2023

India is expected to be the fastest growing market at a CAGR of 6.60% during the forecast period

Regional Analysis:

Asia gastrointestinal drugs market is segmented on the basis of region: China, India, Republic of Korea, and Rest of Asia. Japan accounts for the major share of the market owning to the well-developed technology and high healthcare expenditure. People in this region are more focused on health, which drive the growth of the market. China is the second largest market, which is followed by India. Owing to the government support for the research & development, well-developed healthcare infrastructure, and high health care expenditure drive the China gastrointestinal drugs market. India is the fastest growing gastrointestinal drugs market across the region. Increasing need for the better treatment methods rapidly changing the healthcare sector. Additionally, the presence of huge opportunities for the development of the market have boosted the market growth.

Developing nations, for instance, India is experiencing high demand for gastrointestinal disorder drugs. Major pharmaceuticals drug manufacturers are using their technology and services to develop new drugs for gastrointestinal diseases to meet the growing demand.

Ask for Discount @ https://www.marketresearchfuture.com/check-discount/633 .

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Technologies and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.T

Akash Anand,
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.